Description
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2. Lornoxicam exhibits both anti-inflammatory and analgesic activities. In vivo, lornoxicam decreases herpetic stromal keratitis induced by herpes simplex virus HSV-1 by decreasing activation of NF-κB and expression of TNF-α. In other animal models, lornoxicam decreases levels of prostaglandin E2 (PGE2) and attenuates Freund’s adjuvant-induced hyperalgesia. Lornoxicam also exhibits some antioxidative and neuroprotective activities, decreasing caspase 3 activity and malondialdehyde levels and increasing superoxide dismutase (SOD) levels to prevent neuronal apoptosis in animal models of brain injury.
References
Topcu I, Vatansever S, Bayram E, et al. The effects of lornoxicam on neuroprotection following diffuse traumatic brain injury in rats. Turk Neurosurg. 2013;23(6):764-71. PMID: 24310460.
Yin J, Huang Z, Xia Y, et al. Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice. Mol Vis. 2009 Jun 14;15:1252-9. PMID: 19547717.
Futaki N, Harada M, Sugimoto M, et al. The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. J Pharm Pharmacol. 2009 May;61(5):607-14. PMID: 19405999.
Radhofer-Welte S, Rabasseda X. Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76. PMID: 12879104.
